A Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis (RMS) (NCT05119569)
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis
🩺 Plain-English Summary (8th-Grade Level)
This is a study evaluating the effect of fenebrutinib on brain magnetic resonance imaging (MRI) in participants with RMS. The safety and pharmacokinetics of fenebrutinib will also be evaluated. Participants will be randomized to receive either fenebrutinib or placebo. This study consists of two parts: Double-blind treatment (DBT) phase and an optional Open-label extension (OLE) phase.
Who can join: Review the eligibility criteria below.
Location: Fullerton Neurology and Headache Center — Fullerton, California
Age range: 18 Years to 55 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (17 Sites)
- Fullerton Neurology and Headache Center — Fullerton, California
- Cleveland Clinic Lou Ruvo — Las Vegas, Nevada
- University Clinical Centre of the Republic of Srpska — Banja Luka,
- Clinical Hospital Center Rijeka - PPDS — Rijeka,
- General Hospital Varazdin — Varaždin,
- Klinicki bolnicki centar Zagreb — Zagreb,
- Poliklinika Solmed — Zagreb,
- Nemocnice Jihlava, prispevkova organizace — Jihlava, Vyso?ina
- Fakultni nemocnice u sv. Anny v Brne — Brno,
- Fakultni nemocnice Hradec Kralove — Hradec Králové,
- Vseobecna Fakultni Nemocnice V Praze - CRC - PPDS — Prague,
- Clinical Center of Serbia — Belgrade,
- Military Medical Academy — Belgrade,
- Clinical center Kragujevac — Kragujevac,
- Clinical Center Nis — Niš,
- Clinical Hospital Centre Zemun — Zemun,
- Univerzitna nemocnica Bratislava — Bratislava,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Relapsing Multiple Sclerosis
- A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone) — Cullman, Alabama
- Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis — Maitland, Florida
- Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2) — Phoenix, Arizona
- A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis. — Birmingham, Alabama
- A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS) — Birmingham, Alabama
Explore by condition: All Relapsing Multiple Sclerosis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.